GW Pharmaceuticals

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search

GW Pharmaceuticals PLC
Public Limited Company
Traded asNASDAQGWPH
IndustryPharmaceutical
Founded1998
FounderGeoffrey Guy and Brian Whittle
HeadquartersCambridge,
United Kingdom[1]
Key people
Justin Gover (CEO)[2]
ProductsSativex
Revenue$33.8 million (2001)[3]
DivisionsBiotechnology
Websitewww.gwpharm.com

GW Pharmaceuticals is a British biopharmaceutical company known for its multiple sclerosis treatment product nabiximols (brand name, Sativex) which was the first natural cannabis plant derivative to gain market approval in any country.[4] Another cannabis-based product, Epidiolex, was approved for treatment of epilepsy by the US Food and Drug Administration in 2018.[5]

History[edit]

GW Pharmaceuticals was founded in 1998 by Doctors Geoffrey Guy and Brian Whittle. That year, they obtained a cultivation license from the United Kingdom Home Office and the MHRA, allowing the company to cultivate, possess and supply cannabis to conduct scientific research concerning medicinal uses of the plant.[6][7]

Later that year, GW Pharmaceuticals entered into a contract with HortaPharm B.V., a cannabis research and development corporation based in Amsterdam.[8] The company was founded by two expert horticulturists from California,[9] Robert Connell Clarke[10] and David Paul Watson, and grew and developed specialized strains of cannabis with permission from the Dutch government.[11][12][13][14]

In 2001, GW Pharmaceuticals listed on AIM, the junior market of the London Stock Exchange.[15] In May 2013, the company became dual-listed on the NASDAQ and AIM.[16]

Marketed products[edit]

Sativex[edit]

Nabiximols (trade name Sativex) is a botanical drug that is a cannabis extract, administered as a mouth spray; it was approved in the UK in 2010 as a treatment for multiple sclerosis (MS) patients to alleviate neuropathic pain, spasticity, overactive bladder, and other symptoms.[17]

Nabiximols is made with two unknown Cannabis strains, and is extracted with ethanol and carbon dioxide.[18][19]

In 2011, GW Pharmaceuticals concluded a partnership with Bayer for the distribution of Sativex in the UK,[20] and have an estimated annual production of 100 tons of medicinal cannabis since 2012.[21]

Products in development[edit]

Cannabidiol oral solution[edit]

In 2015 GW Pharmaceutical initiated Phase 3 clinical trials of cannabidiol by mouth for treatment of two orphan conditions in children – Dravet and Lennox-Gastaut syndromes.[22][23] GW also received fast track designation from the US FDA for use of the drug candidate to treat newborns with epilepsy.[24]

The drug, under the brandname Epidiolex, was given US FDA approval in June 2018.[25][26]

See also[edit]

References[edit]

  1. ^ "GW Pharmaceuticals Ltd". 17 August 2017.
  2. ^ https://www.theguardian.com/business/2011/apr/17/gw-pharmaceuticals-justin-gover-cannabis-sativex-multiple-sclerosis?INTCMP=SRCH The Observer, Sunday 17 April 2011)
  3. ^ "Prices and markets Stocks of GW PHARM". Londonstockexchange.com. 28 June 2001.
  4. ^ Elizabeth Landau (21 June 2010). "World's first fully approved cannabis drug on sale in UK". Thechart.blogs.cnn.com.
  5. ^ CNN, Debra Goldschmidt and Susan Scutti. "FDA approves first cannabis-based drug". CNN. Retrieved 7 August 2019.
  6. ^ Pete Brady (25 April 2003). "GW Pharm responds to CC". Cannabisculture.com. Archived from the original on 12 November 2013.
  7. ^ Mary Lynn Mathre, R. N. (July 1997). Cannabis in Medical Practice: A Legal, Historical, and Pharmacological Overview of the Therapeutic Use of Marijuana (Google eBook). ISBN 9780786403615 – via Google Books.
  8. ^ "The Inheritance of Chemical Phenotype in Cannabis sativa L.(HortaPharm B.V., 1075 VS, Amsterdam, The Netherlands and Instituto Sperimentale per le Colture Industriali, 40128 Bologna, Italy)". Genetics.org. 1 January 2003.
  9. ^ "sam-the-skunkman [Four Twenty Wiki]". Fourtwentywiki.com. 16 August 2011.
  10. ^ "inauthor:"Robert Connell Clarke" – Google Search".
  11. ^ Marks, MD; Tian, L; Wenger, JP; et al. (2009). "Seeds from the marijuana cultivar Skunk no. 1 were provided by HortaPharm BV (Amsterdam, The Netherlands) and imported under a US Drug Enforcement Administration (DEA) permit to a registered controlled substance research facility". J. Exp. Bot. 60 (13): 3715–26. doi:10.1093/jxb/erp210. PMC 2736886. PMID 19581347.
  12. ^ "Details released of collaboration between GW Pharmaceuticals and HortaPharm medicinal cannabis". Gwpharm.com.
  13. ^ Breen, Bill (1 February 2004). "The Cannabis Conundrum". Fastcompany.com.
  14. ^ Breen, Bill (1 February 2004). "Dr. Dope's Connection". Fastcompany.com.
  15. ^ "GW Pharma aims for $150m in Nasdaq offering". Financial Times. Retrieved 6 July 2018.
  16. ^ "UK Cannabis Grower on a High With Wall Street Funding Bid". International Business Times UK. 21 December 2013. Retrieved 23 August 2019.
  17. ^ UK Medicines Online Nabiximols Page accessed 3 February 2016
  18. ^ "Extraction of pharmaceutically active components from plant materials". Patentstorm.us.
  19. ^ "Is Big Pharma set to corner the American market on medical marijuana?". Americanindependent.com. 25 April 2011. Archived from the original on 22 July 2012.
  20. ^ "GWPharma – GW and Bayer Announce Marketing Agreement on Pioneering New Cannabis-based Treatment". Gwpharm.com. 30 September 2004.
  21. ^ "Medical Cannabis Strains – Geoffrey Guy, MD (GW Pharmaceuticals, UK (Conference)". Youtube.com. 23 February 2010.
  22. ^ Ward, Andrew (9 January 2014). "GW raises nearly $90m to develop childhood epilepsy treatment". Financial Times. Retrieved 20 January 2014.
  23. ^ Butticè, Claudio (9 December 2015). "Therapeutic Cannabis for children – a possible new treatment for epilepsy". Meds News. Retrieved 3 February 2016.
  24. ^ Tony Quested for Business Weekly. 6 August 2015 FDA backs cannabis-based medicine for in-danger newborns
  25. ^ "FDA approves country's first medicine made from marijuana - STAT". STAT. 25 June 2018. Retrieved 25 June 2018.
  26. ^ Julia Kollewe (25 June 2018), "UK epilepsy drug to become first cannabis-based medicine in US", The Guardian

External links[edit]